Clinical Characteristics and Therapeutic Effect of Rifaximin in Patients with Gastroesophageal Reflux Disease Complicated with Small Intestinal Bacterial Overgrowth
Objective To investigate the clinical features of gastroesophageal reflux disease(GERD)complicated with small intestinal bacterial overgrowth(SIBO)and to further explore the therapeutic effect of rifaximin on these patients.Methods A total of 149 patients(83 males and 66 females)who met the inclusion criteria for gastroesophageal reflux disease admitted to Handan Central Hospital and Handan First Hospital from January 2022 to January 2023 were counted.According to the results of lactulose hydrogen-methane breath test(LHBT),they were divided into GERD with SIBO group(GERD-P group)and non-SIBO group(GERD-N group).The differences between the two groups in general data(gender,age,body mass index)and clinical data(atypical symptoms,extra-esophageal symptoms,complications,endoscopic findings,GERDQ score,RDQ score,GERD-HRQL score)were compared.Then GERD-P group was randomly divided into two groups:one group(treatment group)was given Ⅱaprazole Enteric-coated Tablets(10 mg qd)combined with rifaximin(0.2 g tid)for 4 weeks,and the other group(control group)was given IIaprazole Enteric-coated Tablets(10 mg qd)alone for 4 weeks,and the therapeutic effect of rifaximin was evaluated by clinical data.Results Compared with the GERD-N group,there was no difference in gender ratio and age between the two groups(P＞0.05).BMI,atypical symptoms,extra-esophageal symptoms and complications,endoscopic severity,GERDQ score,RDQ score and GERD-HRQL score in the GERD-P group were all higher than those in the GERD-N group,with statistical significance(P＜0.05).After 4 weeks of treatment,there was no difference in complications between the treatment group and the control group(P＞0.05).The treatment group was superior to the control group in atypical symptoms,extra-esophageal symptoms,endoscopic remission,GERDQ score,RDQ score and GERD-HRQL score,with statistical significance(P＜0.05).Conclusion Patients with high BMI of GERD are more likely to have SIBO.Patients with GERD and SIBO have more severe clinical symptoms and related scale scores than those with GERD and no SIBO.In GERD patients with SIBO,IIaprazole Enteric-coated Tablets combined with rifaximin is clinically superior to IIaprazole Enteric-coated Tablets alone.
万方数据
维普
